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human cancer remains largely circumstantial, but it clearly warrants further study as little is
known about the tumor-inhibitory roles of PITX1 in cutaneous malignant melanoma. The aims
of this study were to investigate PITX1 gene expression in patients with cutaneous malignant
melanoma and to evaluate its potential relevance to clinicopathological characteristics and tu-
mor cell proliferation. Clinicopathological findings of patients with cutaneous malignant mel-
anoma were analyzed retrospectively. PITX1 and Ki-67 expression were detected by
immunohistochemistry in malignant melanoma and healthy tissue samples from each patient.
Labeling indices were calculated based on PITX1 gene and Ki-67 expression. The correlation
between PITX1and Ki-67 expressions was analyzed in cutaneous malignant melanoma cases.
The relationship between PITX1 expression intensity and clinicopathological characteristics
was also analyzed. PITX1 expression was observed in all (100%) normal healthy skin tissue sam-
ples. In addition, PITX1 expression was found in 56 (80%) and was absent in 14 (20%) of the 70
cutaneous malignant melanoma cases. Ki-67 positive expression was only detected in the 14
(20%) PITX1-negative cases. PITX1-positive tumor cells were observed on the surface, but Ki-
67 positive tumor cells were observed in deeper zones of the tumor nests. PITX1 expression
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t of Pathology, Faculty of Medicine, Bulent Ecevit University (formerly Zonguldak Karaelmas
Turkey.
.com (F. Barut).
6.08.001
ng Medical University. Published by Elsevier Taiwan LLC. This is an open access article under the
ecommons.org/licenses/by-nc-nd/4.0/).
PITX1 expression in cutaneous malignant melanoma 495skin tissue, but Ki-67 expression was upregulated in concordance with the progression of cuta-
neous malignant melanoma. PITX1 expression may be involved in tumor progression and is a
potential tumor suppressor gene and prognostic marker for cutaneous malignant melanoma.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
The skin is the most common primary site of malignant
melanoma, a lethal skin cancer that occurs predominantly
in Caucasians [1]. Malignant melanoma originates from
nevus cells and melanocytes; it is associated with poor
prognosis and high mortality because of its high degree of
malignancy, early blood and lymphatic metastasis, and
resistance to chemotherapy and radiotherapy [2,3].
Clinicopathological features and prognostic factors for
melanoma have been widely investigated within different
populations [1,4,5]. The reported incidence of cutaneous
malignant melanoma is high and increasing further. Cuta-
neous melanoma is associated with a high mortality rate,
and early diagnosis and treatment are important for
improving survival rates. Survival depends on tumor thick-
ness and clinical staging on presentation [1,4]. The histo-
logical features of the primary melanoma, including tumor
thickness, mitotic rate, and ulceration, are important
hallmarks of melanoma prognosis and staging [6].
Pituitary homeobox 1 (PITX1/PTX1), also called Backfoot
(BFT), is a bicoid-related homeobox transcription factor
that is involved in the transcription of the pro-
opiomelanocortin (POMC ) gene [7e12]. PITX1 plays a role
in the differentiation and formation of pituitary cells as
well as in the development of the oral epithelium, first
branchial arch, and its derivatives [13]. PITX1 is expressed
throughout the developing hindlimb but not in the forelimb
bud. Misexpression of PITX1 in chick wing buds causes them
to develop into limbs with some morphological character-
istics of hindlimbs [7e11,14].
The evidence that PITX1 is a significant tumor suppressor
gene in human cancer remains largely circumstantial (lung
cancer [7], esophageal adenocarcinoma [8], osteosarcoma
[9], gastric adenocarcinoma [15], colorectal adenocarcinoma
[16]) but is clearly worth further study [15]. PITX1 expression
and its clinical significance in cutaneousmalignantmelanoma
remain unclear, because there are only a few studies on this
subject in the literature; therefore, we focused on the
expression of PITX1 in malignant melanoma tissues.
In this study, we evaluated the intensity of PITX1
expression in cutaneous malignant melanoma cases and
aimed to determine its prognostic significance and its
relevance to clinicopathological characteristics.Methods
Clinicopathological patient data
Clinicopathological data were collected from patient re-
cords and their pathology reports retrospectively. Signedand written informed consent was obtained from all pa-
tients. All patients were diagnosed with cutaneous malig-
nant melanoma in the Department of Pathology, Faculty of
Medicine, Bulent Ecevit University, Zonguldak, Turkey, be-
tween January 2001 and May 2014. None of the patients had
received preoperative anticancer treatment.
In total, 70 patients were evaluated, and clinical and
pathological data were analyzed for each patient. Clinical
characteristics included age and sex. Histological variables
included histogenetic type, Clark level of invasion, Breslow
tumor thickness, and the presence or absence of inflam-
matory infiltration (TIL) and ulceration. All tumors were
classified as melanoma in situ, superficially spreading
melanoma (SSM), lentigo malignant melanoma (LMM),
nodular melanoma (NM), or acral lentiginous melanoma
(ALM). Tumor thickness was considered to be a continuous
variable and was categorized according to the most
recently recommended breakpoints [6]: 1 mm,
1.01e2.00 mm, 2.01e4.00 mm, and > 4 mm. TNM staging
was assessed according to the criteria proposed by the
American Joint Committee on Cancer (AJCC, 2009) [6].
Histopathological examinations were performed on 70
surgically resected cutaneous malignant melanomas and 30
healthy skin tissues. The healthy skin tissues were obtained
from the margins of wide excisions taken from biopsied
patient samples that were negative for dermal tumors. All
specimens were fixed in 10% formalin, embedded in
paraffin, and cut into 3e4-mm-thick sections. Specimens
were then deparaffinized and stained with hematoxylin and
eosin for histological evaluation.
Immunohistochemical examination
Sections (3e4 mm) obtained from representative tissue
sample blocks were deparaffinized with xylene, rehydrated
in a graded alcohol series, and placed in 0.5% hydrogen
peroxide in methanol for 10 minutes to block endogenous
peroxidase activity. Antigen retrieval was performed by
incubation in 0.01M citrate buffer (pH 6.0) for 5 minutes in
a pressure cooker. The sections were exposed to the pri-
mary antibody for 60 minutes at room temperature. The
standard streptavidinebiotineperoxidase complex method
was used for PITX1 (Rabbit-polyclonal, LS-C100923; LSBio,
South San Francisco, CA, USA, 1:50) and Ki-67 (Rabbit-
monoclonal, RM-9106-S; Lab-Vision, Fremont, CA, USA,
1:100). 3,30-Diaminobenzidine tetrahydrochloride was used
as the chromogen. The section was then counterstained
with hematoxylin, rinsed, and mounted. The sections were
evaluated in a single-blinded fashion.
Immunohistochemical examinations of the specimens
were based on a scoring method described by Osaki et al.
[11]. At least 500 melanoma cells in the tumor area were
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clear staining was designated as the labeling index. The
immunoreactivity against PITX1 protein and Ki-67 were
classified into two groups: negative, when < 10% of tumor
cells showed positive signals, versus positive, when at least
10% of tumor cells showed positive signals.
Statistical analysis
Statistical analyses were performed using SPSS 19.0 soft-
ware (SPSS Inc., Chicago, IL, USA). Distribution of the data
was determined using ShapiroeWilk test. Continuous vari-
ables were expressed as median (minimum e maximum) or
means  standard deviation, and categorical variables as
frequencies and percentages. Continuous variables were
compared using the ManneWhitney U test, and categorical
variables were compared using the Chi-square test. A p
value of < 0.05 was considered statistically significant for
all tests.
Results
PITX1 and Ki-67 expression were evaluated in 30 healthy
skin samples and 70 cutaneous malignant melanoma sam-
ples. A diagnosis of malignant melanoma was made based
on hematoxylin and eosin sections and HMB45 expression
(Figure 1).
The correlations between immunohistochemical PITX1
expression and clinicopathological features in the 70 cuta-
neous malignant melanoma samples are shown in Table 1.
PITX1 expression was positive in 56 (80%) and negative in 14
(20%) of the tested melanoma cases. Data from 70 patients
(32 women and 38 men), with a median age of 61.50 years
(range, 16e90 years), were analyzed.
There were no significant differences in age (pZ 0.336)
or sex (pZ 0.589) between the PITX1-positive and PITX1-
negative groups. However, there were significant differ-
ences in ulceration (p< 0.001), TIL (pZ 0.005), thickness
(p< 0.001), Clark’s level (pZ 0.003), histologic subtype
(pZ 0.001), and stage (p< 0.001) between the two groups.
The median (min e max) tumor thickness was 3.0 mm
(range, 1.0e14.0 mm) in the PITX1-positive cases and
7.0 mm (range, 5.0e15.0 mm) in the PITX1-negative cases.
The median tumor thickness was significantly higher in theFigure 1. Histopathological appearance of cutaneous malignant
immunohistochemical HMB45 positivity. B-SAZ 3,30-diaminobenzidPITX1-negative cases compared with the PITX1-positive
cases (p< 0.001).
In this study, the most common histologic subtype was
NM (35 cases), which showed the most frequent PITX1
negativity (nZ 13). The remaining PITX1-negative case
(nZ 1) was the ALM histologic subtype. There were sig-
nificant differences between NM and other histologic sub-
types with respect to ulceration (pZ 0.042), TIL
(pZ 0.028), thickness (p< 0.001), Clark’s level (p< 0.001),
stage (p< 0.001), and PITX1 expression (pZ 0.001).
PITX1-positive (80%) and Ki-67-positive (20%) cases were
analyzed, and their statistically significant correlations
with stage are summarized in Table 2.
All five melanoma in situ cases, which were Stage 0,
were classified as PITX1-positive. All Stage 0 cases (5 of 5,
100%), all Stage I cases (10 of 10, 100%), 40 of 48 Stage II
cases (83.3%), one of four Stage III cases (25%), and no Stage
IV cases (0 of 3, 0%) were PITX1-positive, indicating that
PITX1 expression is downregulated during malignant mela-
noma progression. The number of Ki-67-positive cases was
eight of 48 (16.7%) Stage II patients, three of four (75%)
Stage III patients, and three of three (100%) Stage IV pa-
tients, indicating that Ki-67 expression is upregulated dur-
ing cutaneous malignant melanoma progression.
As shown in Figure 2, PITX1-positive cells and Ki-67-
positive cells present in healthy skin and cutaneous malig-
nant melanoma samples demonstrated that PITX1 and Ki-67
are localized in the nucleus. In all 30 healthy skin samples,
PITX1 was found in all epidermal layers (Figure 2A). The
data indicate that PITX1 is expressed in melanocytes of
healthy skin. Ki-67 immunoreaction was positive only in
epidermal basal cells (Figure 2B). Ki-67 expression was
negative (Figure 2D) in the PITX1-positive malignant mela-
noma cases (Figure 2C) and was positive (Figure 2F) in the
PITX1-negative cases (Figure 2E).
PITX1-positive tumor cells were observed on the surface
but were rare in deeper zones of the tumor nests in cuta-
neous malignant melanoma cases (Figure 3A), suggesting
that PITX1 expression is suppressed in the invasive tumor
front. By contrast, Ki-67-positive tumor cells were observed
in deeper zones of the tumor nests (Figure 3B), suggesting
that Ki-67 expression is highest in the invasive tumor front.
These results indicate that the proliferative activity of
melanoma cells is inversely associated with PITX1
expression.melanoma in (A) hematoxylin and eosin (H&E, 200) and (B)
ine tetrahydrochloride (100).
Table 2 PITX1 and Ki-67 expression positivity and distri-
bution according to stage.
Stage Positive p
PITX1 (nZ 56) Ki-67 (nZ 14)
0 (nZ 5) 5 (100) 0 (0) <0.001
I (nZ 10) 10 (100) 0 (0)
II (nZ 48) 40 (83.3) 8 (16.7)
III (nZ 4) 1 (25) 3 (75)
IV (nZ 3) 0 (0) 3 (100)
Data are presented as n (%).
PITX1Z pituitary homeobox 1.
Table 1 Clinicopathological and immunohistochemical
features of cutaneous malign melanoma.
PITX1 p
Positive
(nZ 56)
Negative
(nZ 14)
Age (y)
Minimum 16 38 0.336
Maximum 83 90
Median, range 60.0 66.5
Sex
Male (nZ 38) 29 (51.8) 9 (64.3) 0.589
Female (nZ 32) 27 (48.2) 5 (35.7)
Ulceration
Yes (nZ 32) 18 (32.1) 14 (100) <0.001
No (nZ 38) 38 (67.9) 0 (0)
Histologic subtype
In situ (nZ 5) 5 (100) 0 (0) 0.001
SSM (nZ 22) 22 (100) 0 (0)
LMM (nZ 1) 1(100) 0 (0)
ALM (nZ 7) 6 (85.7) 1 (14.3)
NM (nZ 35) 22 (62.9) 13 (37.1%)
Inflammatory infiltrate (TIL)
Absent (nZ 31) 30 (53.6) 1 (7.1) 0.005
Present (nZ 39) 26 (46.4) 13 (92.9)
Thickness (mm)
1 (nZ 10) 10 (17.9) 0 (0) <0.001
1.01e2 (nZ 13) 13 (23.2) 0 (0)
2.01e4 (nZ 20) 20 (35.7) 0 (0)
>4 (nZ 27) 13 (23.2) 14 (100)
Clark’s level
0 (nZ 5) 5 (8.9) 0 (0) 0.003
I (nZ 1) 1 (1.8) 0 (0)
II (nZ 8) 8 (14.3) 0 (0)
III (nZ 9) 9 (16.1) 0 (0)
IV (nZ 31) 26 (46.4) 5 (35.7)
V (nZ 16) 7 (12.5) 9 (64.3)
Stage
0 (nZ 5) 5 (8.9) 0 (0) <0.001
I (nZ 10) 10 (17.9) 0 (0)
II (nZ 48) 40 (71.4) 8 (57.1)
III (nZ 4) 1 (1.8) 3 (21.4)
IV (nZ 3) 0 (0) 3 (21.4)
Data are presented as n (%).
ALMZ acral lentiginous melanoma; In situZmelanoma in situ;
LMMZ lentigo malignant melanoma; NMZ nodular melanoma;
PITX1Z pituitary homeobox 1; SSMZ superficially spreading
melanoma.
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In this study, we demonstrated that PITX1 expression is
downregulated in cutaneous malignant melanoma tissues,
compared with healthy skin samples. In addition, PITX1
downregulation was associated with clinical stage pro-
gression in malignant melanoma patients. Increased cell
proliferation has been implicated in the progression of
cutaneous malignant melanoma; therefore, we examined
whether reduced PITX1 expression was correlated with Ki-
67 expression in the malignant melanoma cases. Theprognosis of cutaneous malignant melanoma depends on
the stage. The 2009 AJCC staging criteria [6] for cutaneous
melanoma were based on histological features such as
thickness of the tumor, level of invasion, presence of ul-
ceration/mitoses, and presence of regional and distant
metastases. When we evaluated the relationship between
PITX1 expression and stage, PITX1 expression was signifi-
cantly reduced in advanced stage disease compared with
early stage disease. These data indicate that PITX1 may be
involved in tumor progression and is a potential tumor
suppressor and prognostic marker for cutaneous malignant
melanoma.
Homeodomain transcription factors play fundamental
roles in directing cellular proliferation, differentiation, and
cell fate [17]. A common feature of homeobox genes is the
presence of a highly conserved 61-amino acid motif, the
homeodomain. Several homeobox genes have been impli-
cated in neoplastic development [7,11]. For example,
PITX1 expression is reduced in Barrett’s esophagus and is
significantly reduced during the progression to Barrett’s-
associated adenocarcinoma [8,11]. This phenomenon is also
observed in lung [7], gastric [15], and colon cancer cells
[16] as well as in prostate [18] and bladder cancers, but not
in the respective healthy tissues [11,19,20]. Osaki et al.
[11] demonstrated that PITX1 expression is involved in the
tumorigenesis and/or progression of cutaneous malignant
melanoma.
Osaki et al. [11] reported that 19 (47.5%) out of 40 cases
with primary melanoma were negative for PITX1 expression
and found that PITX1 expression was significantly reduced
during the advanced stage cancers. In this study, 14 (20%) of
70 melanoma samples were negative for PITX1 expression,
and PITX1 expression was significantly reduced in advanced
stage cancers. These results are therefore consistent with
those of Osaki et al. [11]. The low rate of PITX1 negativity
in this study is likely attributable to the small number of
advanced-stage cancer samples (nZ 7) included. Osaki
et al. [11] also reported that the mean tumor thickness in
the PITX1-negative cases (7.11 10.3 mm) was significantly
higher than that in the PITX1-positive cases
(1.90 3.19 mm). The present study also found that PITX1-
negative tumors were thicker; however, tumor thickness
was > 4 mm in all PITX1-negative cases. Tumor thickness
has consistently been reported to be the most important
independent prognostic variable in melanoma [21,22].
Reduced PITX1 expression in cutaneous malignant mel-
anoma was significantly associated with several
Figure 2. PITX1 and Ki-67 expression in healthy skin and cutaneous malignant melanoma samples. (A) PITX1 expression in all
layers of the epidermis and skin appendages of healthy skin. (B) Ki-67 expression in the basal layer of healthy skin epidermis. (C)
PITX1 positivity in cutaneous malignant melanoma (at least 10% of tumor cells showing positive staining in the nuclei). (D) Ki-67
negativity in cutaneous malignant melanoma (< 10% of the labeling index). (E) PITX1 negativity in cutaneous malignant mela-
noma (< 10% of tumor cells showing positive signals). (F) Ki-67 positivity in cutaneous malignant melanoma (> 10% of the labeling
index). B-SAZ 3,30-diaminobenzidine tetrahydrochloride (A, B, 200; CeF 100); PITX1Z pituitary homeobox 1.
Figure 3. (A) PITX1-positive tumor cells on the surface of the tumor nests and (B) Ki-67-positive tumor cells in the deeper zone of
the tumor nests in cutaneous malignant melanoma. B-SAZ 3,30-diaminobenzidine tetrahydrochloride (100); PITX1Z pituitary
homeobox 1.
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metastatic rate, and clinical stage, suggesting that the loss
of PITX1 expression might be a potential biomarker for
cutaneous malignant melanoma malignancy [11]. Similar
results were found in the present study.
The most common histologic subtype reported in the
literature is the SSM [4,5,23] subtype, but in this study, the
most common histologic subtype was NM. In concordance
with our study, Pailoor et al. [1] also found that the most
common histologic subtype was NM (nZ 22) among 24
cutaneous malignant melanoma cases, whereas Luk et al.
[4] reported that the most common histologic subtype was
ALM (50.8%) among 63 cases.
The intermediate filament nestin, a neural stem-cell
marker, is expressed more strongly in melanomas compared
with benign melanocytic lesions, and increased nestin
expression is associated with aggressive NM [24]. Increased
expression of dysadherin, a novel cell membrane glyco-
protein, is a significant indicator of poor prognosis in pa-
tients with cutaneous malignant melanoma and is
significantly correlated with nodular subtype [25]. In the
abovementioned studies, increased nestin and dysadherin
expression was associated with aggressive NM and poor
prognosis. In this study, a relationship between PITX1
negativity and histologic type was found; one of 14 PITX1-
negative cases was the ALM and the remaining the NM
(nZ 13) histologic subtype. Of the four major histologic
types, previous studies have shown that SSM and LMM have
better patient survival rates compared with NM or ALM [21].
Cutaneous malignant melanoma is the most aggressive
skin cancer, and its incidence is increasing worldwide [4].
Although early cutaneous malignant melanoma is curable
by surgical excision, metastases develop in up to 20% of
cases because of a high potential for invasion and rapid
spread to other organs. Cutaneous malignant melanoma has
the highest mortality rates of any cancer, particularly in
advanced cases. Although considerable improvements have
been made in diagnostic techniques, surgical treatment,
chemotherapy, and radiotherapy in recent decades, pa-
tients with advanced cutaneous malignant melanoma still
face a poor prognosis. Therefore, identification of molec-
ular markers to predict the potential for tumor progression
and disease prognosis is needed [11].
Our focus of interest in this study was the relationship
between tumor PITX1 expression and/or progression of
cutaneous malignant melanoma. As there is no clear link
between the reported expression patterns or functions of
PITX1 in cutaneous melanocytes, PITX1 expression in
human cutaneous malignant melanoma was investigated in
this study. The low expression of PITX1 suggested that it has
a tumor suppressive function, which led us to examine the
relationship between PITX1 expression and tumor progres-
sion [11].
PITX1 is a novel human telomerase reverse transcriptase
(hTERT) suppressor gene [17,26,27]. TERT is the principal
component controlling telomerase activity that facilitates
cellular immortalization. PITX1 represses hTERT transcrip-
tion through direct binding to the TERT promoter and
eventually leads to inhibition of telomerase activity and
proliferation [26,27]. PITX1 suppresses tumorigenicity by
downregulating the RAS pathway through RASAL1, a mem-
ber of the RAS-GAP family of genes (GTP-activating factor-negative regulators of RAS) [19,26]. However, the under-
lying mechanisms that are involved in the regulation of
PITX1 remain unknown. Here, Ohira et al. [26] report that
the microRNA-19b (miR-19b) regulates hTERT expression
and cell proliferation through inhibition of PITX1.
Compared with normal melanocyte cells, miR-19b expres-
sion was higher in most melanoma cells and was accom-
panied by downregulation of PITX1. Moreover,
overexpression of miR-19b inhibited PITX1 mRNA trans-
lation through a miR-19b binding site within the 30UTR of
the PITX1 mRNA. Ohira et al.’s [26] combined findings
indicate the participation of miR-19b as a novel upstream
effector of hTERT transcription via direct targeting of PITX1
[26].
Activation of the RAS/MAPK pathway contributes to the
tumorigenesis and progression of cutaneous malignant
melanoma, and inhibition of the pathway could suppress
the proliferation of human melanoma cells [11,28].
Consistent with our study, Osaki et al. [11] showed that
the Ki-67 labeling index, indicative of proliferative activity,
was significantly higher in PITX1-negative tumor areas
compared with PITX1-positive tumor areas. Therefore, they
suggested that loss of PITX1 expression results in activation
of the RAS/MAPK pathway via downregulation of RASAL1,
leading to hyperproliferation of melanoma cells [11]. Our
study supports this conclusion.
The purpose of this study was to reveal the relationship
between PITX1 and cutaneous malignant melanoma.
Downregulation of PITX1 in melanoma cells may be involved
in the progression of cutaneous malignant melanoma; thus,
PITX1 represents a candidate tumor suppressor gene.
Further studies should examine potential mechanisms for
modulating PITX1 expression during the progression of
cutaneous malignant melanoma.References
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